Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2024 10:00 ET | Source: BioNTech SE

Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom

Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem,...
June 01, 2024 10:00 ET | Source: BioNTech SE

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...
June 01, 2024 10:00 ET | Source: Genmab A/S

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival...
May 30, 2024 18:01 ET | Source: Novartis Pharma AG

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
May 29, 2024 08:00 ET | Source: BioNTech SE

BioNTech und CEPI erweitern Partnerschaft zur Stärkung des afrikanischen mRNA-Impfstoff-Ökosystems

BioNTech und die Coalition for Epidemic Prepardness Innovations (CEPI) wollen die lokale Forschung und Entwicklung sowie die klinische und kommerzielle Herstellung potenzieller mRNA-Impfstoffe...
May 29, 2024 08:00 ET | Source: BioNTech SE

BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to...
May 29, 2024 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an...
May 28, 2024 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
May 28, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
May 27, 2024 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry...